Krsnaa Diagnostics share price today

Krsnaa Diagnostics Ltd's share price was ₹483.05 at the close on 4 November 2026. It has been falling for 45 weeks. That is 18.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹483 and ₹817, and at that close it was at the low of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Krsnaa Diagnostics Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running.

Over the last 5.2 years the share price moved −48% while the NIFTY 500 moved +55%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), lowest operating margin in 8 quarters and highest quarterly revenue in 15 quarters.

1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹236 crore, +22.3% on a year earlier.

   Why: Revenue rose because a big Rajasthan contract moved from setup into running services.

   Next results: check whether retail brings in the targeted share of group revenue.

   From the earnings call on 14 Aug 2026.

2. Lowest operating margin in 8 quarters

   Operating margin was 25% in the June 2026 quarter, against 27% a year earlier.

   Why: Margins fell because a big new Rajasthan contract added staff and collection costs before it brought in full revenue.

   Next results: check whether the retail unit stops losing money and helps margins.

   From the earnings call on 14 Aug 2026.

3. Highest quarterly revenue in 15 quarters

   Revenue of ₹236 crore in the June 2026 quarter is the highest of the last 15 quarters.

For April to June 2026 (the quarter ended 30 June 2026), Krsnaa Diagnostics reported revenue of ₹236 crore, up 22.3% from ₹193 crore a year earlier, and a profit of ₹17.0 crore, down 19.0% from ₹21.0 crore.

Krsnaa Diagnostics results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Krsnaa Diagnostics' management discussed these results on a call held on 14 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Krsnaa Diagnostics closed at ₹483.05 on 4 November 2026, down 33.3% from ₹724.30 a year earlier (7 November 2025) and down 28.1% over five years. Its highest weekly close since August 2021 was ₹995.55 on 29 November 2024.

Krsnaa Diagnostics share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

276 weekly closes from 20 August 2021 to 4 November 2026.

4 Nov 2026: Krsnaa Diagnostics closed at ₹483.05, down 4.1% on the week and down 12.9% on the month. 18 Sep 2026: ex-date for a dividend of ₹2 a share.

Earlier

• 14 Aug 2026: Krsnaa Diagnostics held its results call for April to June 2026. Management guided: Rajasthan revenue expected to double in July to September 2026; FY27 clear visibility ₹100-150 crore and steady-state ₹150-175 crore; earlier ₹200-250 crore aspiration retained.
• Results for April to June 2026: Revenue up 22.3% and profit down 19.0% on a year earlier.

Krsnaa Diagnostics paid ₹2 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.41% at the ₹483.05 close on 4 November 2026. The last was a dividend of ₹2 a share, ex-date 18 September 2026.

Krsnaa Diagnostics dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Krsnaa Diagnostics Ltd paid out 6% of its profit as dividends in FY26, and it paid a dividend in 5 of its last 11 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 14 August 2026, Krsnaa Diagnostics' management guided: Rajasthan revenue expected to double in July to September 2026; FY27 clear visibility ₹100-150 crore and steady-state ₹150-175 crore; earlier ₹200-250 crore aspiration retained.

“From a margin perspective, once the Rajasthan operation normalizes in terms of operational maturity, we expect margins to return to double digits by the end of the year as a whole.”Yash Mutha, on the call for April to June 2026

What management guided

• Retail contribution planned at 10-15% of group revenue in FY27.
• RPL expected to become operating profit positive by July to September 2026.
• Remaining Maharashtra MRI centers expected live by the end of October to December 2026.
• Consolidated margins expected to return to double digits by year-end as Rajasthan normalizes.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 14 August 2026.

When Krsnaa Diagnostics reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Rajasthan utilization and sequential revenue ramp next quarter - check fixed-cost absorption and consolidated margin improvement.

Krsnaa Diagnostics is on one of our India lists: 52 week high & low.

Krsnaa Diagnostics Ltd earned ₹17.0 Cr of net profit in the Jun 2026 quarter, −19.0% on the same quarter a year earlier. Full-year FY26 profit was ₹101 Cr. That is 7.2% of the quarter's revenue. The same quarter a year earlier earned ₹21.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹101 Cr (+29.5% on the year before).

Why profit moved: revenue changed +22.3% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +20.0% and revenue +10.1%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Krsnaa Diagnostics Ltd reported ₹236 Cr of revenue in the Jun 2026 quarter, +22.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 34.8% a year on average. The last full year, FY26, came in at ₹773 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹816 Cr.

FY26 revenue was ₹773 Cr, +7.8% on the year before.

Recent pace: the last four quarters grew +10.1% on average, against 34.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +10.3%, against +12.1% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +21.0%, against +27.8% a year (rolling over).

Krsnaa Diagnostics Ltd's operating margin was 25.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 11 years it has been between −57.0% and 41.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −2.0 percentage points on the year while gross margin changed +3.3 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 108% of Krsnaa Diagnostics Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹143 Cr of operating cash against ₹101 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹281 Cr of spending on assets, free cash was −₹138 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 108% of profit came in as cash: the cash cycle got 71 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 2.5× depreciation over three years. The next section checks what that spending is building.

Krsnaa Diagnostics Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 140 days in FY26, up from 69 days in FY21. It spent ₹621 Cr on assets over the last 3 years. Customers take 140 days to pay, and stock sits for 54 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹773 Cr, each day of that cycle ties up about ₹2.1 Cr, so roughly ₹296 Cr is tied up in the business at any time.

FY26: customers took 140 days to pay and stock sat for 54 days, about 1.8 months of sales sitting as stock, for a full cycle of 140 days, longer than FY21's 69.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 54 days. Customers pay about 140 days after that. Suppliers are paid at 129 days. Together that makes the 140-day cycle.

Spending on assets: ₹621 Cr over the last 3 years, against ₹253 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹208 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Krsnaa Diagnostics Ltd's P/E is 16.1×, about the lowest it has ever been. Its usual P/E (the middle reading) is 28.6×, over 4.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +30.1% while the price moved −33.3%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 3 years the price moved −12.4% a year; about +14.6% a year came from earnings growth and about −27.0 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Krsnaa Diagnostics Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 13.4%; each line tells part of the story. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Krsnaa Diagnostics Ltd earned a ROCE of 13% in FY26. That is up from a low of −65% in FY20. Its return on capital used (ROIC) is 4.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a 13.1% net margin and 0.42× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a 13.1% net margin × 0.42× asset turnover × 1.86× leverage (assets divided by equity) ≈ 10.2% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 8.0% − 12.0% = −4.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

Krsnaa Diagnostics Ltd has total debt of ₹534 Cr against shareholder equity of ₹980 Cr as of Jun 2026, so its debt is 0.54× its equity. Year by year, that ratio went from 0.06 in FY22 to 0.54 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions cut their stake in Krsnaa Diagnostics Ltd by 1.4 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 14.5% of the company. Foreign institutions moved +0.2 points over the same period, to 3.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: −1.4 points over 8 quarters, to 14.5%; Foreign institutions: +0.2 points over 8 quarters, to 3.8%; Promoters: −0.1 points over 8 quarters, to 27.1%.

Why the owners changed: domestic institutions drove it (−1.4 points). They reduced their stake.

For Krsnaa Diagnostics Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

49.1 out of 100, rank 8 of 9 in Diagnostics, with 81% of the evidence available.

Krsnaa Diagnostics Ltd scores 49.1 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 8. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far.

The four parts add up to the total exactly: 13.7 + 8.6 + 18.9 + 7.9 = 49.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Krsnaa Diagnostics ranks 8 of 9 Diagnostics companies on the 4-Factor Sector Score, with 49.1 out of 100.